Login to Your Account



'BEST IN CLASS' FOR YEARS TO COME

Dyax deal vindicated: Shire's HAE drug proves mettle in pivotal phase III

By Marie Powers
News Editor

Friday, May 19, 2017

Eighteen months after picking up Dyax Corp. for $5.9 billion in cash, Shire plc appears to have a winner with lanadelumab, originally known as DX-2930. The plasma kallikrein inhibitor, which Shire first designated as SHP-643, met its primary and secondary endpoints with highly statistical significance, compared to placebo, in the phase III HELP study in patients 12 and older with hereditary angioedema (HAE).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription